Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy
CHANHASSEN, Minn., May 15, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM) – one of the most aggressive and deadly forms of brain cancer.
Backed by leading healthcare investors, the round was co-led by HealthQuest Capital and Samsara BioCapital with participation from existing investors OrbiMed and Action Potential Venture Capital. In addition, venture investors committed to transforming cancer care participated, including BrightEdge, the impact investment and innovation arm of the American Cancer Society, the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, and Sontag Innovation Fund, a subsidiary of The Sontag Foundation.
'The complex and diffuse nature of glioblastomas has long hindered therapeutic innovation,' said Conrad Wang M.D., Partner at HealthQuest Capital. 'Alpheus' sonodynamic therapy represents a novel, non-invasive whole brain approach with compelling early data. This investment reflects our commitment to advancing transformative technologies that seek to fill critical gaps in patient unmet needs.'
Alpheus' platform delivers non-thermal, tumor-selective therapy activated by low-intensity diffuse ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA). Without the need for imaging or sedation, this combination selectively targets and destroys cancer cells across the entire brain hemisphere. This novel treatment option is performed in an outpatient setting. Promising early results from two studies highlight the potential of SDT therapy in both newly diagnosed and recurrent glioblastoma patients.
'This investment is a key inflection point for Alpheus and the glioblastoma community – advancing sonodynamic therapy from promise to clinical validation,' commented Vijay Agarwal, MD, FAANS, FCNS, President and CEO of Alpheus Medical. 'With this support, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors.'
About Alpheus Medical, Inc.
Alpheus Medical is a private, clinical-stage oncology company developing a groundbreaking, non-invasive treatment for solid tumors utilizing sonodynamic therapy (SDT). Its proprietary platform combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA), a sensitizing agent that selectively accumulates in tumor cells. This targeted approach aims to destroy cancer cells while sparing healthy tissue. Alpheus collaborates with global leaders in neuro-oncology and is supported by top healthcare investors and the venture vehicles of nonprofit organizations focused on cancer. Learn more at www.alpheusmedical.com.
About HealthQuest Capital
HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately $2 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry. For more information, visit www.healthquestcapital.com.
About Samsara BioCapital
Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs. Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-two years of industry experience and has an MD and a PhD in Immunology from Stanford University.
Media Contact
Carla Benigni
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/alpheus-medical-raises-52m-in-series-b-round-to-advance-groundbreaking-glioblastoma-therapy-302455795.html
SOURCE Alpheus Medical
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
01-07-2025
- Yahoo
China ready to discuss tariffs and subsidies with US at WTO
By Olivia Le Poidevin GENEVA (Reuters) -China is ready to have discussions about trade policies, including tariffs and subsidies, that Washington has identified as obstacles to reforming the World Trade Organization, a senior delegate at China's mission to the WTO said. China had heard "every word" the U.S. had said at the WTO about its trade practices and is open to discussing tariffs, industrial policy and some benefits it gains from its developing country status, as part of broader conversations on reform ahead of a 2026 ministerial meeting in Cameroon, the delegate said. The official declined to be identified. China's mission does not publicly identify delegates below ambassador rank. China recalled its WTO ambassador in April to become a trade negotiator and the vacant position has yet to be filled. The delegate's remarks follow months of trade tension between the world's two largest economies over sweeping tariffs imposed by the U.S. and retaliatory measures by China. Washington argues there can be no meaningful WTO reform until China and other major economies relinquish privileges known as Special and Differential Treatment (SDT) granted to developing countries, which the U.S. says give them an unfair advantage. Some major economies, including China and Saudi Arabia, self-identify as developing countries, granting them access to SDT benefits such as setting higher tariffs and using subsidies. The delegate said China's developing country status was non-negotiable, but it might forgo SDT in upcoming negotiations, as it did recently on fisheries and domestic regulations. "I see that in the coming negotiations, generally speaking, I don't think China will ask for the SDT," the delegate told Reuters. However, former WTO spokesperson Keith M. Rockwell, a senior research fellow at the Hinrich Foundation, was sceptical that China would fully relinquish SDT in areas like agriculture. The U.S. opposes countries picking and choosing SDT benefits, and wants China to completely renounce them. The delegate said China was open to discussing subsidies to ensure a fairer playing field provided it was met with goodwill in return. But it would not accept any attempts to try to change its economic system, they added. Following positive trade talks in Geneva and London, China indicated openness towards discussing tariffs within the WTO. "We welcome the U.S. to come back to the WTO," the delegate said. "We are ready to renegotiate on Article 28 if the U.S. raises their requests here at the WTO." Article 28 of the WTO Agreement allows members to modify tariff commitments under certain conditions, providing a potential pathway for adjustments. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-06-2025
- Business Wire
ByteDance Purchases more than 100,000 Units of Rubicon Carbon's Flagship Product, The Rubicon Carbon Tonne ®
MARINA DEL REY, Calif.--(BUSINESS WIRE)-- Rubicon Carbon, a leading carbon credit management firm, announced today that ByteDance, the global technology company behind content platforms including TikTok, has purchased the right to retire more than 100,000 tonnes of carbon credits. The credits were purchased through Rubicon Carbon's flagship carbon credit offering, the Rubicon Carbon Tonne ® (RCT), and represent a milestone on ByteDance's path toward achieving its carbon neutrality target by 2030 while also underscoring the company's commitment to high-integrity climate action. Rubicon Carbon Tonnes (RCTs) are actively managed portfolios of high-quality carbon credits from global projects, including nature-based, super pollutant, and carbon removal initiatives. Rubicon's science team ensures ongoing monitoring and integrity. Buyers secure access to premium credits at today's prices, reducing exposure to future cost spikes and supply issues. With expert management, RCTs offer confidence that retired credits will meet the highest standards and deliver measurable climate impact. The RCTs acquired by ByteDance include a carefully curated mix of nature-based avoidance credits and carbon removal credits designed to deliver both immediate climate impact and long-term carbon dioxide removal. 'We are thrilled to welcome ByteDance as a buyer of Rubicon Carbon Tonnes,' said Tom Montag, CEO of Rubicon Carbon. 'ByteDance's decision to invest in RCTs signals a serious, long-term commitment to climate leadership and a recognition that the path to net zero must be built on high-quality, durable carbon solutions. We're proud to play a role in helping them meet that goal.' To achieve its carbon neutrality goals by 2030, ByteDance aims to reduce at least 90% of its operational emissions, with the remaining 10% offset by carbon credits. Rubicon Carbon's team provided ByteDance with robust educational resources and advisory support, helping the company evaluate its purchases in the voluntary carbon market with confidence. 'We greatly appreciate the time and expertise that the Rubicon Carbon team invested to help us make high-value and impactful decisions within the carbon credit landscape,' said Ian Gill, Global Head of Sustainability at ByteDance. 'As we advance toward our 2030 carbon neutrality goal, it's critical that we build long-term relationships with trusted partners. This purchase marks an important step in that journey, and we look forward to continuing our collaboration with Rubicon Carbon.' The announcement builds on Rubicon Carbon's continued momentum as a trusted partner to global organizations seeking scalable, science-based climate solutions. The company's unique approach to carbon credit sourcing — combining rigorous project selection with a portfolio-based structure — ensures that every Rubicon Carbon Tonne meets the highest standards of environmental integrity. For more information about Rubicon Carbon and the Rubicon Carbon Tonne, visit About Rubicon Carbon: Rubicon Carbon is a carbon credit management firm that empowers the world's largest enterprises to achieve their sustainability goals by addressing carbon emissions and driving global climate finance. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking carbon avoidance and removal projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit About ByteDance: Founded in 2012, ByteDance's mission is to inspire creativity and enrich life. With a suite of more than a dozen products, including TikTok, Helo, and Resso, as well as platforms specific to the Chinese market, including Toutiao, Douyin, and Xigua, ByteDance has made it easier and more fun for people to connect with, consume, and create content. ByteDance's investors include Coatue, General Atlantic, KKR, Sequoia Capital, SIG, and Softbank.
Yahoo
16-06-2025
- Yahoo
Epic Group, Creative Group to boost fashion manufacture in India
The JV was initiated under the leadership of Epic Group chairman Ranjan Mahtani, and in partnership with Creative Group, which is led by chairman Vijay Agarwal. The collaboration was marked by a non-binding memorandum of understanding (MOU) signed on 9 January 2025, which has now been formalised through a shareholder agreement. The venture is supported by an initial funding of $15m and aims to reach a turnover of Rs5bn ($60m) in the foreseeable future. Under the Spectra JV, the inaugural project is a denim and bottoms manufacturing plant with the capacity to manufacture 700,000 units monthly. Spectra will lay emphasis on sustainable practices, innovative approaches, and initiatives that contribute to community growth. Some of the key features of the initiative include use of renewable energy sources to maintain a reduced carbon footprint; creation of 3,000 jobs initially, with the goal of increasing employment opportunities to 10,000 as operations expand; and introduction of advanced manufacturing techniques for apparel production. Combining the manufacturing expertise of Epic Group with Creative Group's 50 years track record in textiles, the collaboration seeks to deliver value to clients, associates, and stakeholders and contribute to India's ascent as a leading centre for eco-friendly garment manufacturing. 'We remain grateful for the opportunity to work alongside dedicated teams and partners who share our vision. This is just the beginning, and we look forward to sharing more updates as Spectra grows and evolves,' said Epic Group. "Epic Group, Creative Group to boost fashion manufacture in India" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
